Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
HRTX
HRTX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
HRTX News
Heron (HRTX) Q4 2025 Earnings Call Transcript
Feb 26 2026
NASDAQ.COM
Heron Therapeutics Q4 2025 Earnings Highlights
Feb 26 2026
seekingalpha
Heron Therapeutics Q4 Earnings Report Analysis
Feb 26 2026
seekingalpha
Heron Therapeutics to Announce Q4 Earnings on February 26
Feb 25 2026
seekingalpha
Heron Therapeutics Reports Q4 2025 Net Revenue of $40.5M Driven by ZYNRELEF and APONVIE
Jan 10 2026
Yahoo Finance
Heron Therapeutics Reports $154.9M Net Revenue for 2025
Jan 09 2026
Globenewswire
Daily Upgrade Report for Validea's James P. O'Shaughnessy Strategy - December 18, 2025
Dec 18 2025
NASDAQ.COM
Heron Launches APONVIE for Rapid Prevention of Postoperative Nausea and Vomiting
Dec 04 2025
Globenewswire
Heron Therapeutics Reveals APONVIE® (aprepitant) Injectable Emulsion Added to Updated Fifth Consensus Guidelines for Postoperative Nausea and Vomiting (PONV) Management
Dec 04 2025
Yahoo Finance
Daily Upgrade Report for Validea's James P. O'Shaughnessy Strategy - November 13, 2025
Nov 13 2025
NASDAQ.COM
Heron Therapeutics Inc. Reports Larger Q3 Loss, Falls Short of Expectations
Nov 04 2025
NASDAQ.COM
Heron Therapeutics, Inc. Adopts Tax Benefits Preservation Plan to Protect NOL Assets and Shareholder Value
Aug 15 2025
Newsfilter
Wednesday 8/13 Insider Buying Report: WBD, HRTX
Aug 13 2025
NASDAQ.COM
Heron Therapeutics (HRTX) Reports Q2 Loss, Misses Revenue Estimates
Aug 08 2025
NASDAQ.COM
Heron Therapeutics Announces Q2 2025 Financial Results and Highlights Commercial Progress
Aug 08 2025
Newsfilter
Heron Therapeutics announces capital restructuring to support growth
Aug 08 2025
SeekingAlpha
Show More News
